Bioventus Inc.BVS
What Bioventus Inc. does.
Unless the context requires otherwise, in this Annual Report on Form 10-K (“Annual Report”) the terms “we,” “us,” “our,” the “Company,” “Bioventus,” “Bioventus Inc.” and similar references refer to the combined operations of Bioventus Inc. and its consolidated subsidiaries and affiliates, including Bioventus LLC (“BV LLC”).
We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing musculoskeletal challenges through a diverse portfolio of high-quality, innovative, and clinically-proven solutions. We manage our business through two reporting segments, U.S. and International, which accounted for 88% and 12%, respectively, of our total net sales during the fiscal year ended December 31, 2025.
Our portfolio of products is comprised of five patient-focused areas, grouped into three businesses based on clinical use: (i) Pain Treatments & PRP (“Pain Treatments”), (ii) Surgical Solutions and (iii) Restorative Therapies.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $321.2M | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Net income | $16.4M | $19.4M | -$158.7M | -$156.2M | -$36.1M | $22.7M |
| Free cash flow | $55.2M | $9.5M | -$15.0M | $8.0M | $37.8M | $72.1M |
More on BVS.
- Bioventus Inc. summary
- Bioventus Inc. financial statements
- Bioventus Inc. key metrics
- Bioventus Inc. health scores and style box
- Bioventus Inc. earnings
- Bioventus Inc. dividends
- Bioventus Inc. valuation
- Bioventus Inc. ownership and insiders
- Bioventus Inc. peers
Figures from Bioventus Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.